Alpha 2.0
Login Register
» Authors » Hiroshi Miyakita

Hiroshi Miyakita

Explore the profile of Hiroshi Miyakita including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 28
Citations 155
Followers 0
Related Specialties
Oncology
General Medicine
General Surgery
Top 10 Co-Authors
Kazutake Okada
Sotaro Sadahiro
Toshiyuki Suzuki
Takashi Ogimi
Gota Saito
Akira Tanaka
Lin Fung Chan
Seiichiro Yamamoto
Yutaro Kamei
Hiroshi Kajiwara
Published In
Oncology
Tokai J Exp Clin Med
Anticancer Res
BMC Gastroenterol
Am J Surg
Affiliations
Soon will be listed here.
Recent Articles
11.
Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial
Sadahiro S, Suzuki T, Okada K, Saito G, Miyakita H, Ogimi T, et al.
Oncology . 2020 Jun; 98(9):637-642. PMID: 32474564
Background: FOLFIRI plus bevacizumab have been widely used as first-line treatment for metastatic colorectal cancer (mCRC). Pharmacokinetics and pharmacodynamics suggested a low dose of irinotecan given as a long-term infusion...
12.
A prospective clinical study assessing the presence of exfoliated cancer cells and rectal washout including tumors in patients who receive neoadjuvant chemoradiotherapy for rectal cancer
Okada K, Sadahiro S, Kamei Y, Chan L, Ogimi T, Miyakita H, et al.
Surg Today . 2019 Oct; 50(4):352-359. PMID: 31637511
Purpose: Rectal washout is performed in rectal cancer surgery to eliminate exfoliated cancer cells. Before rectal washout, a cross-clamp should generally be placed distal to the tumor. In some patients...
13.
Preventive effects of a synthetic absorbable antiadhesive film (seprafilm) on small bowel obstruction in patients who underwent elective surgery for colon cancer: A randomized controlled trial
Saito G, Sadahiro S, Ogimi T, Miyakita H, Okada K, Tanaka A, et al.
J Surg Oncol . 2019 Aug; 120(6):1038-1043. PMID: 31392725
Background: Seprafilm did not decrease small bowel obstruction (SBO), but significantly decreased reoperation in patients with inflammatory bowel disease. However, the preventive effect in colon cancer remains unclear. Methods: We...
14.
Distribution of Neuroendocrine Marker-Positive Cells in Colorectal Cancer Tissue and Normal Mucosal Tissue: Consideration of Histogenesis of Neuroendocrine Cancer
Ogimi T, Sadahiro S, Kamei Y, Chan L, Miyakita H, Saito G, et al.
Oncology . 2019 Aug; 97(5):294-300. PMID: 31390635
Background: Colorectal neuroendocrine carcinoma (NEC) is a rare disease, and mixed cases with colorectal adenocarcinoma also exist. The histogenesis of this disease remains unclear. We studied the numbers of neuroendocrine...
15.
Usefulness of Preoperative Mechanical Bowel Preparation in Patients with Colon Cancer who Undergo Elective Surgery: A Prospective Randomized Trial Using Oral Antibiotics
Suzuki T, Sadahiro S, Tanaka A, Okada K, Saito G, Miyakita H, et al.
Dig Surg . 2019 May; 37(3):192-198. PMID: 31055568
Background: To prevent surgical site infection (SSI) in colorectal surgery, the combination of mechanical bowel preparation (MBP), oral antibiotic bowel preparation (OABP), and the intravenous antibiotics have been proposed as...
16.
Induction of CD3+ and FoxP3+ T Cells in Left-sided Colorectal Tumors After UFT/LV Chemotherapy
Sadahiro S, Suzuki T, Tanaka A, Okada K, Saito G, Miyakita H, et al.
Anticancer Res . 2019 Apr; 39(4):1997-2005. PMID: 30952743
Background/aim: Immune checkpoint inhibitors are mainly used for right-sided, microsatellite instability-high colorectal tumors. In this study, the effects of oral uracil-tegafur plus leucovorin (UFT/LV) chemotherapy on the gene expressions of...
17.
Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer
Tanaka A, Sadahiro S, Suzuki T, Okada K, Saito G, Miyakita H
Oncol Lett . 2018 Oct; 16(5):6589-6597. PMID: 30344762
Regorafenib and trifluridine/tipiracil (TAS-102) are novel antitumor agents for patients with refractory metastatic colorectal cancer. However, it is unclear which patients may derive a survival benefit from these drugs in...
18.
The Number of Natural Killer Cells in the Largest Diameter Lymph Nodes Is Associated with the Number of Retrieved Lymph Nodes and Lymph Node Size, and Is an Independent Prognostic Factor in Patients with Stage II Colon Cancer
Okada K, Sadahiro S, Chan L, Ogimi T, Miyakita H, Saito G, et al.
Oncology . 2018 Aug; 95(5):288-296. PMID: 30138925
Objective: We previously reported that the largest diameter of retrieved lymph nodes (LNs) correlates with the number of LNs and is a prognostic factor in stage II colon cancer. We...
19.
Chemoradiotherapy-induced Changes in Mucinous Components in Rectal Cancer Tissue: Evaluation on High Iron Diamine-alcian Blue and Mucin 1 Staining
Miyakita H, Sadahiro S, Kamei Y, Ogimi T, Saito G, Okada K, et al.
Anticancer Res . 2018 Aug; 38(8):4783-4787. PMID: 30061249
Background/aim: The standard treatment for rectal cancer is neoadjuvant chemoradiotherapy (nCRT) followed by surgery. Mucinous carcinoma responds poorly to nCRT. In some patients, mucin lakes (MLs) are induced by nCRT....
20.
Outcomes of Local Excision plus Chemoradiotherapy in Patients with T1 Rectal Cancer
Suzuki T, Sadahiro S, Tanaka A, Okada K, Saito G, Miyakita H, et al.
Oncology . 2018 Jun; 95(4):246-250. PMID: 29909419
Objective: The National Comprehensive Cancer Network (NCCN) guidelines recommend local excision and observation as standard treatment for selected patients with clinical T1N0M0 rectal cancer. In patients with pathological T1 (pT1)...